Boehringer Ingelheim

SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

Phase 3Not yet recruiting350 people2 Oct 2026clinicaltrials.gov

NCT07850063

Phase 3Not yet recruiting600 people30 Sept 2026clinicaltrials.gov

NCT07850050

Phase 3Not yet recruiting600 people30 Sept 2026clinicaltrials.gov

NCT07845630

Phase 1Not yet recruiting36 people29 Sept 2026clinicaltrials.gov

NCT07754461

Phase 3Recruiting600 people10 Aug 2026clinicaltrials.gov

A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or Overweight

Phase 1Active, not recruiting48 people9 Jul 2026clinicaltrials.gov

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

Phase 3Recruiting466 people21 Apr 2026clinicaltrials.gov

NCT07368569

Phase 1Completed14 people26 Jan 2026clinicaltrials.gov

NCT07221591

Phase 1Completed100 people28 Oct 2025clinicaltrials.gov

NCT07215260

Phase 1Completed14 people10 Oct 2025clinicaltrials.gov

NCT07107945

Phase 3Recruiting120 people6 Aug 2025clinicaltrials.gov

NCT07071974

Phase 1Completed16 people18 Jul 2025clinicaltrials.gov

NCT07064473

Phase 3Recruiting11,800 people14 Jul 2025clinicaltrials.gov

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

Phase 2Active, not recruiting81 people25 Jun 2025clinicaltrials.gov

NCT07035457

Phase 1Completed15 people25 Jun 2025clinicaltrials.gov

A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

Phase 2Recruiting300 people8 May 2025clinicaltrials.gov

NCT06962826

Phase 1Completed14 people8 May 2025clinicaltrials.gov

NCT06955260

CollaboratorPhase 3Recruiting410 people2 May 2025clinicaltrials.gov

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

Phase 3Recruiting4,200 people20 Apr 2025clinicaltrials.gov

NCT06926660

Phase 2Completed492 people14 Apr 2025clinicaltrials.gov

Effects of SGLT-2 Inhibitors on Plasma Concentrations and Renal Clearance of the Risk Marker Trimethylamine-N-Oxide in Patients With Type-2 Diabetes

1 Nov 2026api.crossref.org

Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes

1 Oct 2026api.crossref.org

Survodutide reduces weight in adults with diabetes and obesity

The New England journal of medicine2 Oct 2026